Designer Benzodiazepines’ Activity on Opioid Receptors: A Docking Study
Author
Catalani, Valeria
Botha, Michelle
Corkery, John Martin
Guirguis, Amira
Vento, Alessandro
Schifano, Fabrizio
Attention
2299/25953
Abstract
BACKGROUND: Previous studies have reported that benzodiazepines (BZDs) seem to enhance euphoric and reinforcing properties of opioids in opioid users so that a direct effect on opioid receptors has been postulated, together with a possible synergistic induction of severe side effects due to co use of BDZs and opioids. This is particularly worrisome given the appearance on the market of designer benzodiazepines (DBZDs), whose activity/toxicity profiles are scarcely known. OBJECTIVES: This study aimed to evaluate, through computational studies, the binding affinity (or lack thereof) of 101 DBZDs identified online on the kappa, mu, and delta opioid receptors (K, M, DOR); and to assess whether their mechanism of action could include activation of the latter. METHODS: MOE® was used for the computational studies. Pharmacophore mapping based on strong opioids agonist binders' 3D chemical features was used to filter the DBZDs. Resultant DBZDs were docked into the crystallised 3D active conformation of KOR (PDB6B73), DOR (PDB6PT3) and MOR (PDB5C1M). Co-crystallised ligands and four strong agonists were used as reference compounds. A score (S, Kcal/mol) representative of the predicted binding affinity, and a description of ligand interactions were obtained from MOE®.RESULTS: The docking results, filtered for S < -8.0 and the interaction with the Asp residue, identified five DBZDs as putative binders of the three ORs : ciclotizolam, fluloprazolam, JQ1, Ro 48-6791, and Ro 48-8684.CONCLUSION: It may be inferred that at least some DBZDs may have the potential to activate opioid receptors. This could mediate/increase their anxiolytic, analgesic, and addiction potentials, as well as worsen the side effects associated with opioid co-use.
Publication date
2022-09-22Published in
Current Pharmaceutical DesignPublished version
https://doi.org/10.2174/1381612828666220510153319Other links
http://hdl.handle.net/2299/25953Metadata
Show full item recordRelated items
Showing items related by title, author, creator and subject.
-
Synthesis, biological evaluation, and SAR studies of 14β-phenylacetyl substituted 17-cyclopropylmethyl-7, 8-dihydronoroxymorphinones derivatives : Ligands with mixed NOP and opioid receptor profile
Kumar, Vinod; Polgar, Willma E.; Cami-Kobeci, Gerta; Thomas, Mark P.; Khroyan, Taline V.; Toll, Lawrence; Husbands, Stephen M. (2018-09-19)A series of 14β-acyl substituted 17-cyclopropylmethyl-7,8-dihydronoroxymorphinone compounds has been synthesized and evaluated for affinity and efficacy for mu (MOP), kappa (KOP), and delta (DOP) opioid receptors and ... -
BU10038 as a safe opioid analgesic with fewer side-effects after systemic and intrathecal administration in primates
Kiguchi, Norikazu; Ding, Huiping; Cami-Kobeci, Gerta; Sukhtankar, Devki D.; Czoty, Paul W.; DeLoid, Heather B.; Hsu, Fang Chi; Toll, Lawrence; Husbands, Stephen M.; Ko, Mei Chuan (2019-06-01)Background: The marked increase in mis-use of prescription opioids has greatly affected our society. One potential solution is to develop improved analgesics which have agonist action at both mu opioid peptide (MOP) and ... -
Novel Synthetic Opioids (NSO) Use in Opioid Dependents Entering Detoxification Treatment
Specka, Michael; Kuhlmann, Thomas; Bonnet, Udo; Sawazki, Jürgen; Schaaf, Luzia; Kühnhold, Stefan; Steinert, Renate; Grigoleit, Torsten; Eich, Helmut; Zeiske, Benita; Niedersteberg, Antje; Steiner, Katharina; Schifano, Fabrizio; Scherbaum, Norbert (2022-06-01)Introduction: Over the last decade, the use of New/Novel Synthetic Opioids (NSO) has emerged as an increasing problem, and especially so in the USA. However, only little is known about the prevalence and history of NSO use ...